JP MORGAN/CALL/VERTEX PHARMACEUTICALS/450/0.1/17.01.25

JP MORGAN/CALL/VERTEX PHARMACEUTICALS/450/0.1/17.01.25 Share Price

DE000JB47B02

Market Closed - Börse Stuttgart 08:21:10 01/07/2024 BST
5.53 ^EUR	-4.33%

Current month	-4.33%
1 month	+24.83%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/CALL/VERTEX PHARMACEUTICALS/450/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex to Announce Second Quarter 2024 Financial Results on August 1	07-01	BU
Verve Therapeutics, Inc. Announces Board Appointments	06-28	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT

More news

Quotes 5-day view

Date	Price	Change
01/07/24	5.53	-4.33%
28/06/24	5.78	-2.86%
27/06/24	5.95	+1.54%
26/06/24	5.86	-3.14%
25/06/24	6.05	+9.01%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 08:21 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JB47B0
ISIN	DE000JB47B02
Date issued	18/10/2023
Strike	450 $
Maturity	17/01/2025 (200 Days)
Parity	10 : 1
Emission price	2.96 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	6.92 €
Lowest since issue	1.97 €
Delta	0.67x
Omega	5.165
Premium	8.5x
Gearing	7.68x
Moneyness	1.047
Difference Strike	-21.25 $
Difference Strike %	-4.72%
Spread	0.2 €
Spread %	3.44%
Theoretical value	5.710
Implied Volatility	31.21 %
Total Loss Probability	41.48 %
Intrinsic value	1.979
Present value	3.731
Break even	511.33 €
Theta	-0.09x
Vega	0.12x
Rho	0.13x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.2 USD

Average target price

468.3 USD

Spread / Average Target

-0.63%

Consensus